文献速递慢性肾脏病血液净化与透析

尿素与慢性肾脏病:世纪回归?(尿毒症研究领域)

Urea and chronic kidney disease: the comeback of the century? (in uraemia research).
PubMed 文献 · Nephrol Dial Transplant · 2018-01-01

综述指出,传统上被认为生物学惰性的尿素在慢性肾脏病(CKD)代表性浓度下具有毒性,可诱导胰岛素抵抗、自由基产生、凋亡及肠道屏障破坏等分子改变,并通过氰酸盐、氨和氨甲酰化产物参与动脉粥样硬化等病理过程。观察性临床研究中氨甲酰化产物与心血管及全因发病率和死亡率相关。这些发现重新审视了Kt/Vurea作为透析充分性标志物的有效性,但尿素动力学不能代表其他尿毒症潴留溶质动力学、尿素不能解释全部尿毒症综合征的观点仍然成立。

要点

  • 至少五项研究提示尿素本身可诱导胰岛素抵抗、自由基产生、凋亡及肠道屏障破坏等分子改变。
  • 尿素是氰酸盐、氨和氨甲酰化产物的来源,氨甲酰化参与动脉粥样硬化相关的翻译后蛋白修饰。
  • 观察性临床研究中氨甲酰化产物与心血管及全因发病率和死亡率相关。

核心结论

  • 近期实验数据提示尿素在CKD代表性浓度下具有毒性,对Kt/Vurea作为透析充分性标志物的有效性提出新思考。
  • 尿素动力学不能代表其他尿毒症潴留溶质动力学、尿素不能解释全部尿毒症综合征的观点仍然成立。

研究设计与样本

  • 综述,未报告系统检索范围。

主要发现

  • 至少五项研究表明尿素本身诱导胰岛素抵抗、自由基产生、凋亡及肠道保护屏障破坏等相关分子改变。
  • 尿素是氰酸盐、氨和氨甲酰化产物的来源,氨甲酰化参与动脉粥样硬化等功能的翻译后蛋白修饰。
  • 观察性临床研究中氨甲酰化产物与心血管及全因发病率和死亡率相关。

临床怎么用

  • 未来改善CKD患者结局的努力可指向进一步清除与尿毒症综合征相关的溶质,包括但不限于尿素。
  • 未来努力还需考虑肠道和(残余)肾功能对溶质浓度的影响。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Urea, a marker of uraemic retention in chronic kidney disease (CKD) and of adequacy of intradialytic solute removal, has traditionally been considered to be biologically inert. However, a number of recent experimental data suggest that urea is toxic at concentrations representative for CKD. First of all, at least five studies indicate that urea itself induces molecular changes related to insulin resistance, free radical production, apoptosis and disruption of the protective intestinal barrier. Second, urea is at the origin of the generation of cyanate, ammonia and carbamylated compounds, which as such all have been linked to biological changes. Especially carbamylation has been held responsible for post-translational protein modifications that are involved in atherogenesis and other functional changes. In observational clinical studies, these carbamylated compounds were associated with cardiovascular and overall morbidity and mortality. These findings shed new light on the validity of Kt/Vurea as a marker of dialysis adequacy. Yet, also the views that the kinetics of urea are not representative of the kinetics of several other uraemic retention solutes, and that urea cannot be held responsible for all complex metabolic and clinical changes responsible for the uraemic syndrome, still remain valid. Future efforts to improve the outcome of patients with CKD might be directed at further improving removal of solutes implied in the uraemic syndrome, including but not restricted to urea, also taking into account the impact of the intestine and (residual) renal function on solute concentration.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Vanholder R, Gryp T, Glorieux G, et al. Urea and chronic kidney disease: the comeback of the century? (in uraemia research). Nephrol Dial Transplant. 2018. PMID: 28407121. doi:10.1093/ndt/gfx039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。